Limin Niu

机构：Henan Cancer Hospital, Shandong First Medical University · ORCID：0000-0002-9236-8018

发表论文 64 篇 · 总被引 982 次 · h-index 14

代表论文

• Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial (2023 · Nature Communications · 被引 14)
• Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial (2024 · EClinicalMedicine · 被引 11)
• Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10‐year, single‐center, real‐world study of 67 cases (2023 · Cancer Medicine · 被引 9)
• Diagnostic diversity and heterogeneity of tumors: a real-world study of metastasis re-biopsy in advanced breast cancer (2022 · Chinese Medical Journal · 被引 9)
• Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study. (2024 · Journal of Clinical Oncology · 被引 7)
• Utidelone Plus Bevacizumab for ERBB2 -Negative Metastatic Breast Cancer and Active Brain Metastases (2025 · JAMA Oncology · 被引 5)